Additionally, Breast Tumour Kinase (BRK), a non-receptor type tyrosine kinase, has been found to confer resistance to tamoxifen treatment in breast cancer through the regulation of CDK1 tyrosine phosphorylation (187). Here, CDK1 is linked to breast cancer.